nFront brings operational support and capital to companies across various stages of development. The core focus is on fast growing, capital efficient, software propositions in Europe and the U.S.

Nauta Capital is a technology-focused transatlantic venture capital fund with offices in London, Barcelona and Boston. As an Investment Manager at Nauta Capital, Magnus drove the firm’s investment initiatives across Northern Europe, out of London.Core responsibilities included deal origination, deal flow management, competitor and market review, deal closing activities and post-deal portfolio management.Transactions included among others the €2.8m Series A investment in ChannelSight and the €6.5m Series B investment in BeMyEye, the latter involving both the investment and an acquisition of a key competitor in France as part of a wider European expansion strategy.

• Advised The Press Association on its sale of MeteoGroup to General Atlantic; created cash-flow model and conducted investor returns, implied multiple regression, debt capacity, LBO, comparable company, precedent transaction and DCF analyses; helped devise strategy for future industry consolidation• Advised business intelligence company in sales process to private equity; negotiated engagement letter and non-disclosure agreements; developed financial model; created management presentation and in-depth information memorandum with executive summary, investment highlights, market overview, competitive differentiation, product details and financial overview

• Advised ~$1bn medical device company in sell-side process; conducted DCF, Comparable Company and Precedent Transaction analysis; responsible for creation of management presentation, executive summary and board materials such as process updates and progress plans• Advised 2 pharmaceutical companies in sell-side processes; created in-depth financial model and probability adjusted DCF with multiple scenario analysis• Advised Targacept, Inc. and Aegerion Pharmaceuticals, Inc. on their ~$75 million and ~$65 million follow-on offerings, respectively- Sole firm representative leading investor presentations in New York and Boston as part of Cyclacel Pharmaceuticals, Inc.'s ~$10 million underwritten offering

• Constructed and pitched cross-border acquisition alternatives to European industrial companies, involving valuation through has-gets, DCF, LBO and multiples analysis• Participated in developing and strengthening EuroConsult’s client relationships by assisting in the preparation of new business presentations and project reports

• Tracked potential pair trades where the spread had become abnormally wide or narrow• Analysed prospective investments in real estate sector; mapped assets through online research and cold-calling of property managers, and cooperated with senior team to locate undervalued assets

• Performed preliminary due diligence on potential investment opportunities by evaluating competitive advantages, uniqueness of technology, international potential and management team• Took part in negotiations related to the combination of two portfolio companies in the transportation sector